Atlas Trials

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Clinical trial NCT03775486 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03775486
Sponsor
AstraZeneca
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer NSCLC
Start date
2018-12-21
Primary completion
2021-01-11
Enrollment
401

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.